Study: Effects of Kre-Celazine® On Site-specific Inflammation and Pain

EFX Sports™ Partners With Billings Wolves Football
November 7, 2014
Is Your Protein Spiked? Part 2
November 15, 2014
Show all

Study: Effects of Kre-Celazine® On Site-specific Inflammation and Pain

A Single-Center, Double-Blind Placebo Controlled Study to Evaluate the Efficacy of Kre-Celazine®, an Oral Buffered Creatine-Cetylated Fatty Acid Compound, in its Ability to Reduce Site-specific Inflammation and Pain

Jeff Golini, Margaret Beeson, N.D., Deborah Angersbach, N.D., Jeff Moore, N.D., Patricia Holl, D.C., Chrissy Amicone, N.D., Wendy L. Jones, MS
All American Pharmaceutical; Yellowstone Naturopathic Clinic, Billings Montana; Royal Knight Incorporated, Rochester Minnesota

Published in the Journal of the American Nutraceutical Association (JANA) – Volume 12, No. 1, 2009

Background

Immune-related joint degenerative conditions are expected to strike more than 27 million Americans during the next decade. It is the primary reason for doctor visits and increased health care costs.

Cetylated fatty acids have been reported to exhibit an anti-inflammatory activity in join/muscle and ligament regions in animal studies.

In cell culture studies, creatine monohydrate is capable of modulating certain aspects of cell surface/pro-inflammatory reactant interactions.

Creatine is used by athletes who are engaged in high-energy, ergo-dynamic supportive function, however until recently, very little attention has been paid to its ability to influence cell surface interactions.

Study Objective

Determine whether an oral, alkali buffered creatine–cetylated fatty acid compound was capable of reducing site-specific arthritis with its chronic joint and muscle related inflammation and pain.

Participants and Method

A total of 35 subjects (21 males, 14 females) ranging in ages 23 to 88, experiencing at least one area of chronic, localized joint/tissue pain and stiffness, underwent an extensive pre-screening process to confirm a diagnosis of arthritis.

Volunteers were divided into two groups: ‘Group A’ (n = 24) received 3 grams of Kre-Celazine® daily (4 capsules in all), and ‘Group B’ (n = 11) the same number of capsules of a placebo daily, for 30 days. In addition, participants were required to complete a weekly pain journal, comply with blood draws and examination schedules, according to the protocol.

Results

(Detailed numbers can be seen by clicking the Research Poster Presentation image below)

Summary

Our findings indicate that Kre-Celazine® is the most effective for the reduction of arthritis pain and stiffness involving the extremities such as hand, wrist, and elbow, as well as neck and shoulder regions.

Research Poster Presentation Image:

Dr. Jeff Golini
Dr. Jeff Golini
Dr. Jeff Golini is the Founder, CEO and Executive Scientist of All American Pharmaceutical. He holds numerous patents for innovative compounds such as, Kre-Alkalyn buffered creatine monohydrate, Karbolyn, the high-performance carbohydrate, and Kre-Celazine.

Comments are closed.